Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JEFFREY RIES

NPI
1780647735
CMS profile
217123
Location
UPLAND, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$64.23

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $63.40 1
Education $0.83 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Teva Pharmaceuticals USA, Inc. $63.40 1
Retrophin, Inc. $0.83 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JEFFREY RIES

NPI 1780647735 · CMS profile ID 217123

UPLAND, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1780647735?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JEFFREY RIES, NPI 1780647735, CMS profile ID 217123. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1780647735?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JEFFREY RIES, NPI 1780647735, CMS profile ID 217123. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1780647735?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JEFFREY RIES, NPI 1780647735, CMS profile ID 217123, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1780647735?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $64.23 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Retrophin, Inc. $0.8307/12/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701818687 CMS
Teva Pharmaceuticals USA, Inc. $63.4006/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697880239 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $64.23 2
PY2022 $1,872.84 11
PY2024 $1,254.06 9

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,063.51 9
PY2025 Principal investigator $206,042.38 82
PY2024 Principal investigator $233,005.53 42
PY2023 Recipient $4,662.00 3
PY2023 Principal investigator $237,413.37 35
PY2022 Principal investigator $275,295.64 21
PY2021 Principal investigator $31,781.00 3
PY2020 Recipient $2,280.12 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $687.00 12/31/2022 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMEN
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 889828195
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $8,813.00 11/23/2022 Non-covered Recipient Entity
DR'S ZIMBROFF & MOSKOVITZ INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL OF FIXED-DOSE BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN THE TREATMENT OF ADULTS WITH POST-TRAUMATIC STRESS DISORDER No dispute reported 06/30/2026 933761947
Principal investigator 1 F. Hoffmann-La Roche AG $10,622.00 11/03/2022 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANA
FEN PH II RMS No dispute reported 06/30/2026 950699338
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $6,000.00 10/27/2022 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 933401961
Principal investigator 1 ABBVIE INC. $1,700.00 10/20/2022 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMEN
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 889816923
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $60,232.74 09/02/2022 Non-covered Recipient Entity
Pacific Clinical Research Management Group
Proof of concept and DRF in BPD No dispute reported 06/30/2026 949202089
Principal investigator 1 Boehringer Ingelheim International GmbH $83.32 09/01/2022 Non-covered Recipient Entity
Pacific Clinical Research Management Group
Proof of concept and DRF in BPD No dispute reported 06/30/2026 965112451
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $233.58 09/01/2022 Non-covered Recipient Entity
Pacific Clinical Research Management Group
Proof of concept and DRF in BPD No dispute reported 06/30/2026 949198553
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $762.75 07/21/2022 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ? 6 to <18 Years of Age No dispute reported 06/30/2026 933394423
Principal investigator 1 ABBVIE INC. $8,950.00 06/29/2022 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMEN
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 889797411
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $3,597.00 06/09/2022 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 933389635
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,221.30 06/09/2022 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 933389643
Principal investigator 1 Hoffmann-La Roche Limited $10,547.25 06/02/2022 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANA
FEN PH II RMS No dispute reported 06/30/2026 950730603
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $2,147.00 05/19/2022 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 933387755
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $2,999.25 05/19/2022 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 933387761
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $2,999.25 03/29/2022 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents 6 to <18 Years of Age No dispute reported 06/30/2026 933383305
Principal investigator 1 Hoffmann-La Roche Limited $1,500.00 02/08/2022 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANA
FEN PH II RMS No dispute reported 06/30/2026 950750863
Principal investigator 1 Hoffmann-La Roche Limited $250.00 02/08/2022 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANA
FEN PH II RMS No dispute reported 06/30/2026 950750869
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,797.00 02/03/2022 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents 6 to <18 Years of Age No dispute reported 06/30/2026 933379159
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $141,953.20 02/03/2022 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL OF FIXED-DOSE BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN THE TREATMENT OF ADULTS WITH POST-TRAUMATIC STRESS DISORDER No dispute reported 06/30/2026 933760743
Principal investigator 1 Supernus Pharmaceuticals, Inc. $8,200.00 02/02/2022 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NV-5138 IN ADULTS WITH TREATMENT RESISTANT DEPRESSION No dispute reported 06/30/2026 965509331